Evidence map›Paper›PMID 36498479›Full record

ArticleJournal of clinical medicine2022

Free Light Chains, High Mobility Group Box 1, and Mortality in Hemodialysis Patients.

Antonio Lacquaniti, Susanna Campo, Giuseppe Falliti, Daniele Caruso, Romana Gargano, Elena Giunta, Paolo Monardo

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Antonio LacquanitiNephrology and Dialysis Unit, Papardo Hospital, 98158 Messina, Italy.ORCID 0000-0003-1705-8770
Susanna CampoNephrology and Dialysis Unit, Papardo Hospital, 98158 Messina, Italy.
Giuseppe FallitiClinical Pathology Unit, Papardo Hospital, 98158 Messina, Italy.
Daniele CarusoClinical Pathology Unit, Papardo Hospital, 98158 Messina, Italy.
Romana GarganoDepartment of Economics, University of Messina, 98122 Messina, Italy.ORCID 0000-0003-3985-3820
Elena GiuntaMicrobiology and Virology Unit, Papardo Hospital, 98158 Messina, Italy.
Paolo MonardoNephrology and Dialysis Unit, Papardo Hospital, 98158 Messina, Italy.ORCID 0000-0002-0492-5022
Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte · ITUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Uremic toxins are associated with immune dysfunction and inflammation. The inadequate removal by hemodialysis (HD) of serum free light chains (FLCs) determines their accumulation. This study evaluated FLCs in HD patients, analyzing their relations with other biomarkers, such as serum high mobility group box 1 (HMGB1). Methods: FLC and HMGB1 were evaluated in a cohort of 119 HD patients. κFLC and λFLC were summated to give a combined (c) FLC concentration. Patients were followed prospectively until the end of the observation period of four years, or until the endpoint: the patient’s death. Results: cFLC values in HD patients were 244.4 (197.9−273.5) mg/L. We detected a significant reduction in CD8+ cells and a decreased CD4+/CD8+ ratio. HMGB1 levels were 94.5 (55−302) pg/mL. After multivariate analysis, cFLCs correlated with β2-microglobulin and the CD4+/CD8+ ratio. Subjects with cFLC values above 263 mg/L and with sHMGB1 values < 80 pg/mL experienced a significantly faster evolution to the endpoint (mean follow-up time to progression of 27.5 and 28.5 months, respectively; p < 0.001). After an adjusted multivariate Cox analysis, cFLCs were associated with 11% increased risk of death, whereas low sHMGB1 increased this risk by 5%. Conclusions: cFLCs and HMGB1 reflect the inflammation and immune dysfunction in HD patients representing two strong and independent risk markers of mortality.

Indexed as

CD4+/CD8+ ratiofree light chainshemodialysisHMGB1uremic toxin

Identifiers

PMID36498479
PMCPMC9739300
OpenAlexW4309729073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.